Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer.
about
Therapeutic targeting of a robust non-oncogene addiction to PRKDC in ATM-defective tumors.Exosomes-mediate microRNAs transfer in breast cancer chemoresistance regulationThe role of p53 in cancer drug resistance and targeted chemotherapyCurrent perspectives on CHEK2 mutations in breast cancer.Chemosensitivity and p53; new tricks by an old dogATM-depletion in breast cancer cells confers sensitivity to PARP inhibition.TP53 status predicts long-term survival in locally advanced breast cancer after primary chemotherapy.Low ATM protein expression in malignant tumor as well as cancer-associated stroma are independent prognostic factors in a retrospective study of early-stage hormone-negative breast cancer.A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatmentsATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin.Prevalence of the CHEK2 R95* germline mutationMapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers.Loss of ataxia-telangiectasia-mutated protein expression correlates with poor prognosis but benefits from anthracycline-containing adjuvant chemotherapy in breast cancer.Health risks for ataxia-telangiectasia mutated heterozygotes: a systematic review, meta-analysis and evidence-based guideline.Progression inference for somatic mutations in cancer.Regulation of stem cells-related signaling pathways in response to doxorubicin treatment in Hs578T triple-negative breast cancer cells.Clinicopathological significance of ATM-Chk2 expression in sporadic breast cancers: a comprehensive analysis in large cohorts.TP53 Mutations in Breast and Ovarian Cancer.Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo.High PTEN gene expression is a negative prognostic marker in human primary breast cancers with preserved p53 function.Outcome after surgery for primary hyperaldosteronism may depend on KCNJ5 tumor mutation status: a population-based study from Western Norway.ATM Signaling Pathway Is Implicated in the SMYD3-mediated Proliferation and Migration of Gastric Cancer Cells.53BP1 loss induces chemoresistance of colorectal cancer cells to 5-fluorouracil by inhibiting the ATM-CHK2-P53 pathway.Molecular and clinical features of the TP53 signature gene expression profile in early-stage breast cancer.Study on the Mechanism of Cell Cycle Checkpoint Kinase 2 (CHEK2) Gene Dysfunction in Chemotherapeutic Drug Resistance of Triple Negative Breast Cancer Cells.
P2860
Q27852340-ADC6D6F4-0C0D-4CAB-AEE2-5DAA2EB7444CQ28066991-A74A1267-48BC-4A9B-A440-FDFDE6EA3E9DQ28072553-07908734-8C67-45CC-B32E-71A685BAF733Q33712610-F61744B2-DAD1-4A0F-A96E-D78F3845C2ACQ33739325-78C78F85-E683-40B8-B073-9B38EE797E20Q34249365-22C02DBF-75D8-4D61-AF5E-FD3E9AC6B5D9Q34576275-002D0E1F-77F0-4EAD-8086-5C4D612EF03BQ35676851-F2F4BC97-063E-4736-BCFA-F01386829948Q36740744-29FFD211-C672-4FC3-ADB8-8AF130395E60Q36967158-576A8180-076B-451F-8DF2-DB626F5E5E8CQ37291784-BC2F6E82-4019-4EE7-9DEE-20BED419ABE1Q38087850-946D7598-34EE-4A2A-A6DF-C1551B25EEFAQ38413284-2F0D6626-9ED5-4468-945B-FB378AF2D508Q38667866-2065E634-AF6A-4863-9948-BACD47F85EA1Q38793244-76078E31-D27B-4437-B37C-7DE408B0EDDDQ38851695-31691660-65A0-4AC8-99DC-567EFF246846Q38937671-57F1BC0B-9C01-4542-9E14-F497AD42E540Q38999130-30C4B249-14AF-4442-AEB9-100828F70D51Q40907746-C5E727BF-7306-4886-9895-A82FFC892FD8Q41899812-A04A9B23-3F64-4DD9-B3FE-01E0A2D4DED1Q46675832-F1546C8A-29C5-47B3-9581-9A80CBF8D00EQ47116779-8B95A37C-F2E7-490D-B426-78970F871A70Q51067087-FDC608A2-79D5-48DF-8D45-DCDC8F850C16Q51759206-D21A1064-9082-4C8E-8233-8A91F3AB1DA6Q54109834-D443DA52-9B78-4770-8467-B744CA557A1A
P2860
Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Low expression levels of ATM m ...... chemotherapy in breast cancer.
@ast
Low expression levels of ATM m ...... chemotherapy in breast cancer.
@en
type
label
Low expression levels of ATM m ...... chemotherapy in breast cancer.
@ast
Low expression levels of ATM m ...... chemotherapy in breast cancer.
@en
prefLabel
Low expression levels of ATM m ...... chemotherapy in breast cancer.
@ast
Low expression levels of ATM m ...... chemotherapy in breast cancer.
@en
P2093
P2860
P50
P356
P1476
Low expression levels of ATM m ...... chemotherapy in breast cancer.
@en
P2093
Beryl Leirvaag
Bjørn Østenstad
Erik Løkkevik
Hrvoje Miletic
Ingvil Mjaaland
Ranjan Chrisanthar
Terje Risberg
P2860
P2888
P356
10.1186/BCR3147
P577
2012-03-15T00:00:00Z
P5875
P6179
1034005187